Navigation path

NATT


New Approaches to Target Tuberculosis
 
 
Framework programme:
 7
Contract/Grant agreement number:
222965
EC contribution:
2,900,000 €
Duration:
36 months
Funding scheme:
Collaborative Project (SICA)
Starting date:
01/10/2008
Project Web site:
-
 
 

Keywords: Mycobacterium tuberculosis, new target inhibitors, latent infection

Background

The increasing emergence of multidrug and extensively drug resistant strains of Mycobacterium tuberculosis, the last one being virtually untreatable, urgently demands novel drugs for tuberculosis (TB).

TB can be treated by chemotherapy. Normally, combinations of three to four drugs of first order are given over a period of four to six months. The protracted course of treatment and the side effects lead to a high proportion of non-compliance patients. This and other reasons have led to the increasing emergence of multidrug-resistant (MDR) strains which need inclusion of second-order drugs into the treatment scheme.

More recently there has been an increasing occurrence of extensively drug resistant (XDR) TB strains, so-called XDR TB; this has been recorded in 38 nations so far and is virtually untreatable. The increasing incidences of MDR- and XDR-TB urgently call for novel drugs for TB therapy.

[+] Read More